Komori
Presentation materials for financial results4569KYORIN Pharmaceutical Co.,Ltd.Pharmaceuticals

Supplementary Financial Results Materials for the First Quarter of the Fiscal Year Ending March 2027

In the first quarter of the fiscal year ending March 2027, revenue declined 1.9% year on year and operating profit fell 59.3%, resulting in lower revenue and earnings. The company has not changed its second-quarter or full-year earnings forecasts or its annual dividend forecast.

Worth reading
50Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Deterioration
Direction inferred from the company’s description.
Scale
-1404
¥ millions (year-on-year change in operating income)
Wording
Conditional
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportFirst quarter of the fiscal year ending March 20274 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥29,654 million-1.9%
Operating profit¥964 million-59.3%
Ordinary income¥1,241 million-52.7%
Net income¥824 million-60.8%
Selling, general and administrative expenses112 Hundreds of millions of yen
Results for the three months of the current quarterRevenue of ¥29.7 billion, operating profit of ¥1.0 billion, ordinary profit of ¥1.2 billion, and quarterly net income attributable to owners of the parent of ¥0.8 billion. New drugs and related products (domestic): ¥21.1 billion; new drugs (overseas): ¥0.1 billion; generic drugs: ¥8.5 billion.
Full-year earnings forecast
Net Sales
¥121,800 million
Operating profit
¥2,000 million
Ordinary income
¥2,300 million
Profit attributable to owners of the parent
¥1,500 million
Annual Dividend
¥25 per share
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales24.3％
Operating profit48.2％
Ordinary income54.0％
Profit attributable to owners of the parent55.0％
New drugs, etc. (Japan)25.2％
New drugs (overseas)44.0％
Generic Pharmaceuticals22.3％
Beova27.4％
Lasvic21.6％
Flutiform24.7％
Lifnua21.0％
Mucodyne16.6％
Pentasa26.6％
Desalex63.4％
Kipres30.4％
Milton21.5％
Rubista26.2％
Montelukast tablets “KM”24.4％
Mometasone nasal spray “Kyorin”11.9％
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
  • Revenue decline¥575 million decrease
  • Decrease in gross profit¥1.083 billion decrease
  • Increase in SG&A expenses¥321 million increase
  • Increase in R&D expenses¥390 million increase
  • Selling, general and administrative expenses excluding research and development expenses¥100 million decrease
  • Continued operating profit decline¥1.4 billion decrease
New initiatives
  • Started sole promotion of Sirturo in Japan (from June 2026)
  • Entered into a co-promotion agreement in Japan for Alesion ophthalmic ointment (July 2026)
  • Terminated the license agreement with aTyr for KRP-R120 and removed it from the development pipeline
  • Decided not to exercise the option right for CYR-064 and removed it from the development pipeline
Key KPIsA metric the company considers important as a management benchmark.
  • Beova revenue73 Hundreds of millions of yen
    Year on year against the same period last year+¥1.1 billion (+17.5%)
  • Lasvic sales19 Hundreds of millions of yen
    Year on year against the same period last year-¥100 million (-3.7%)
  • Flutiform sales30 Hundreds of millions of yen
    Year on year against the same period last year-¥300 million (-7.9%)
  • Pentasa sales27 Hundreds of millions of yen
    Year on year against the same period last year-¥500 million (-14.6%)
  • Desalex sales15 Hundreds of millions of yen
    Year on year against the same period last year-¥500 million (-25.6%)
  • Montelukast tablets “KM” revenue25 Hundreds of millions of yen
    Year on year against the same period last year+¥300 million (+13.2%)
Annual Dividend
Annual dividend of ¥25 per share (interim and year-end breakdown: Not disclosed)
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredFirst quarter of the fiscal year ending March 2027
Net Sales¥29,654 million (YoY -1.9%)
Operating profit¥964 million (YoY -59.3%)
Ordinary income¥1,241 million (YoY -52.7%)
Net income¥824 million (YoY -60.8%)
Selling, general and administrative expenses112 Hundreds of millions of yen
Results for the three months of the current quarterRevenue of ¥29.7 billion, operating profit of ¥1.0 billion, ordinary profit of ¥1.2 billion, and quarterly net income attributable to owners of the parent of ¥0.8 billion. New drugs and related products (domestic): ¥21.1 billion; new drugs (overseas): ¥0.1 billion; generic drugs: ¥8.5 billion.
Full-year earnings forecastNet Sales ¥121,800 million / Operating profit ¥2,000 million / Ordinary income ¥2,300 million / Profit attributable to owners of the parent ¥1,500 million / Annual Dividend ¥25 per share
Progress against full-year forecastNet Sales 24.3％ / Operating profit 48.2％ / Ordinary income 54.0％ / Profit attributable to owners of the parent 55.0％ / New drugs, etc. (Japan) 25.2％ / New drugs (overseas) 44.0％ / Generic Pharmaceuticals 22.3％ / Beova 27.4％ / Lasvic 21.6％ / Flutiform 24.7％ / Lifnua 21.0％ / Mucodyne 16.6％ / Pentasa 26.6％ / Desalex 63.4％ / Kipres 30.4％ / Milton 21.5％ / Rubista 26.2％ / Montelukast tablets “KM” 24.4％ / Mometasone nasal spray “Kyorin” 11.9％
Breakdown of Factors Affecting the ChangeFactors Revenue decline / Amount ¥575 million decrease, Factors Decrease in gross profit / Amount ¥1.083 billion decrease, Factors Increase in SG&A expenses / Amount ¥321 million increase, Factors Increase in R&D expenses / Amount ¥390 million increase, Factors Selling, general and administrative expenses excluding research and development expenses / Amount ¥100 million decrease, Factors Continued operating profit decline / Amount ¥1.4 billion decrease
Key KPIsIndicator name Beova revenue / Value 73 Hundreds of millions of yen / Year on year against the same period last year +¥1.1 billion (+17.5%), Indicator name Lasvic sales / Value 19 Hundreds of millions of yen / Year on year against the same period last year -¥100 million (-3.7%), Indicator name Flutiform sales / Value 30 Hundreds of millions of yen / Year on year against the same period last year -¥300 million (-7.9%), Indicator name Pentasa sales / Value 27 Hundreds of millions of yen / Year on year against the same period last year -¥500 million (-14.6%), Indicator name Desalex sales / Value 15 Hundreds of millions of yen / Year on year against the same period last year -¥500 million (-25.6%), Indicator name Montelukast tablets “KM” revenue / Value 25 Hundreds of millions of yen / Year on year against the same period last year +¥300 million (+13.2%)
Annual DividendAnnual dividend of ¥25 per share (interim and year-end breakdown: Not disclosed)
New initiativesStarted sole promotion of Sirturo in Japan (from June 2026), Entered into a co-promotion agreement in Japan for Alesion ophthalmic ointment (July 2026), Terminated the license agreement with aTyr for KRP-R120 and removed it from the development pipeline, Decided not to exercise the option right for CYR-064 and removed it from the development pipeline
Items this document does not state (17)
Gross Profit MarginOperating profit marginSelf-assessment against the planSegment resultsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Gross profit declined by ¥1.083 billion due to lower revenue, while selling, general and administrative expenses increased by ¥321 million, including a ¥390 million increase in research and development expenses. The main factors behind the decline in revenue were the impact of drug price revisions and a decrease in revenue related to gatifloxacin among new drugs (overseas), reflecting the absence of the prior-year contribution.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Financial Results Materials for the First Quarter of the Fiscal Year Ending March 2027 | KYORIN Pharmaceutical Co.,Ltd. (4569) timely disclosure | Komori